来源：中国发展高层论坛过去的2021年，世纪疫情与国际变局持续交织，我国“两个一百年”奋斗目标历史交汇，中国与世界在激荡中复苏，企业和个人在磨砺中前行。这一年，在中国，许多行业与企业迎接着全新的发展机遇和行业趋势；这一年，为中国，世界500强与行业领先企业的商业领袖们变中求新、变中求进，深耕中国，携手共进，共创未来。今年的“CDF之声”栏目邀请参会代表分享过去一年来自己与所领导的企业、所在行业的经历以及他们的感悟。今天做客CDF之声的是辉瑞公司董事长兼首席执行官艾伯乐（Albert Bourla）。艾伯乐认为中国持续推进经济开放与改革的成果和所有人的努力都息息相关，他表示辉瑞非常荣幸能够参与其中。他表示，辉瑞已为中国患者引入60余个创新产品，推进中国公共卫生事业发展，延长患者寿命，改善患者生活…截至目前在华投资超过15亿美元。他指出，辉瑞的使命是为患者带来改变其生活的突破创新。为此，他表示辉瑞将大力支持中国政府的开放举措，支持中国监管制度和保障体系向国际最佳实践不断靠拢以鼓励创新。艾伯乐表示，在当前的非常时期，服务全球患者既是荣幸，也是沉甸甸的责任。他认为，新冠肺炎疫情让我们意识到了科学的力量、筑牢卫生体系的重要性，以及世界是紧密相连的。“如果我们团结协作，没有什么事情做不到。”以下为中英文原文：我在纽约向大家问好！我是辉瑞公司董事长兼首席执行官艾伯乐，很荣幸担任今年中国发展高层论坛外方主席。作为年度盛会，中国发展高层论坛是全球商界及各界人士了解中国政府未来发展愿景的重要机会，同时，这也是我们分享各自观点的机会。中国持续推进经济开放与改革的努力与我们大家都息息相关，非常荣幸能够参与其中。如大家所知，辉瑞在中国已经开展业务很多年。中国向外国投资者敞开大门时，辉瑞就是首批进入的跨国药企之一。自那时以来，我们有幸亲眼见证了中国了不起的经济转型。目前，辉瑞在中国约有7000名员工，在上海和武汉设有两处研发中心，在无锡设立了先进生产基地。上海和武汉的研发中心已成为辉瑞亚太区业务的重要创新枢纽。我们已为中国患者引入60余个创新产品，推进中国公共卫生事业发展，延长患者寿命，改善患者生活…．．．截至目前在华投资超过15亿美元。能够积极参与中国卫生体系这些年的发展，我们感到自豪，并对未来的持续参与充满期待！辉瑞的使命非常明确：为患者带来改变其生活的突破创新。为践行这一使命，我们一定要确保这些突破创新能够切实帮助到那些有需求的患者，包括中国患者。为此，我们大力支持中国政府的开放举措，支持中国监管制度和保障体系向国际最佳实践不断靠拢以鼓励创新。当然，要做的还有很多。我们呼吁进一步深化改革，并愿意随时提供支持。在当前的非常时期，服务全球患者既是荣幸，也是沉甸甸的责任。新冠肺炎疫情让我们意识到了科学的力量、筑牢卫生体系的重要性，以及世界是紧密相连的。疫情还教会我们，如果我们团结协作，没有什么事情做不到。我非常高兴能与大家齐聚中国发展高层论坛，论坛让来自全球各行各业的同仁有机会相聚、思考、聆听、分享和协作。让我们携手共建一个健康、繁荣的新世界，期待在2022年中国发展高层论坛期间会面！谢谢！Greetings from New York City！ My name is Albert Bourla， and I am Chairman and CEO of Pfizer． I am also honored to serve as the Chairman of Foreign Delegates at this year’s China Development Forum．The China Development Forum is an important event because it provides a critical opportunity for the global business community and other stakeholders to hear from the Chinese Government on its vision for the future．  At the same time， we have a chance to share our perspective．  China’s continuing efforts to open and reform its economy is of great interest to us all， and we welcome the opportunity to play our part．As some of you may know， Pfizer has a long history in China．More than thirty years ago， when China opened its doors to foreign investors， we were one of the first multinational pharmaceutical companies on the ground．Since those early days， we have been privileged to witness firsthand China’s remarkable economic transformation．Today， Pfizer has nearly 7，000 employees in China， including colleagues at two R&D centers in Shanghai and Wuhan—which serve as critical innovation hubs for Pfizer’s Asia-Pacific operations—and a state-of-the-art manufacturing facility in Wuxi．We have introduced more than 60 innovative products that advance public health and extend and improve life for Chinese patients…and invested more than 1.5 billion U.S． Dollars in China to date． We are proud of the active role we have played in China’s health system throughout these many years， and look forward to continuing our work for generations to come．Pfizer has a very clear purpose： breakthroughs that change patients’ lives．To fulfill our purpose， we must ensure our breakthroughs get to patients that need them—including patients in China． That is why we have supported the Chinese government’s ongoing efforts to open up to the world and drive innovation by moving China’s regulatory and reimbursement systems closer to international best practices．Of course， there is still more to do． We encourage even deeper reforms and stand ready and willing to support these efforts.During this unprecedented time， it is both a great privilege and a huge responsibility to serve patients around the world． The COVID-19 pandemic has taught us many things about the power of science， the importance of resilient healthcare systems， and how interconnected our world really is． It also has taught us that nothing is impossible if we work together．That is why I am so excited to be joining you at this year’s China Development Forum． This important event offers us a chance to pause， come together， listen， share， and collaborate—across sectors and across borders． Let’s build a healthy， prosperous new world together． I look forward to seeing you at the 2022 China Development Forum！Thank you．责任编辑：李墨轩